Stocks Health care LYEL
NASDAQ · Health careLyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. brought in $27K of revenue over the twelve months to June 30, 2026, down 55.0% from a year earlier. It posted a net loss of $248.5M. In fiscal 2025 capital spending exceeded operating cash flow by $150.8M. At June 30, 2026 it held $73M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Lyell Immunopharma, Inc. does
Lyell Immunopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LYEL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $36K | -$274.4M | -$16.06 | -$150.8M |
| 2024 | $61K | -$343M | -$26.23 | -$162.9M |
| 2023 | $130K | -$234.6M | -$18.70 | -$166.4M |
| 2022 | $84.7M | -$183.1M | -$14.88 | -$193.8M |
| 2021 | $10.7M | -$250.2M | -$37.00 | -$191.8M |
| 2021 | $7.8M | -$204.5M | -$315.49 | -$212.4M |
Where LYEL ranks in Health care
Latest SEC filings
What Lyell Immunopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 10, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 6, 2026
- July 13, 2026
- June 18, 2026Passive stake changed SCHEDULE 13G/A
- June 15, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 11, 2026Passive stake changed SCHEDULE 13G/A
- May 8, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Lyell Immunopharma, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $193.4K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 10, 2026 | Shook DavidChief Medical Officer | Sold | 500 | $6.4K |
| August 21, 2026 | Seely LynnPresident and CEO, Director | Sold | 9,589 | $149K |
| August 21, 2026 | Hill Stephen J.Chief Operating Officer | Sold | 989 | $15.4K |
| August 21, 2026 | Lee Gary K.Chief Scientific Officer | Sold | 1,457 | $22.6K |
Questions about LYEL
What does Lyell Immunopharma, Inc. do?
Lyell Immunopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker LYEL.
Is Lyell Immunopharma, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $248.5M on revenue of $27K.
How much revenue does Lyell Immunopharma, Inc. make?
Over the twelve months to June 30, 2026 Lyell Immunopharma, Inc. reported revenue of $27K. That is 55.0% less than a year earlier.
When did Lyell Immunopharma, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 10, 2026.
Similar companies
Compare LYEL with
Follow LYEL
Get an email when Lyell Immunopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow LYEL: get an email when it filesWhere the numbers come from
Financial figures are the values Lyell Immunopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.